Search

Displaying results 3191 - 3200 of 4692 in total
  1. Drug

    Idarubicin

    go.drugbank.com/drugs/DB01177
    ApprovedInvestigational

    An orally administered anthracycline antineoplastic. The compound has shown activity against breast cancer, lymphomas and leukemias, together with the potential for reduced cardiac toxicity.

  2. Drug

    LGD2941

    go.drugbank.com/drugs/DB05234
    Experimental

    LGD2941 is a non-steroidal, selective androgen receptor modulator (SARM) developed jointly by Ligand and TAP.

  3. Drug

    Actelion-1

    go.drugbank.com/drugs/DB05367
    Experimental

    Actelion-1 is a tissue-targeting Endothelin Receptor Antagonist that has been discovered by Actelion Pharmaceuticals.

  4. Drug

    Rolofylline

    go.drugbank.com/drugs/DB12670
    Investigational

    Rolofylline is under clinical development by pharmaceutical company NovaCardia for the treatment of congestive heart failure.

  5. Drug

    KF-0210

    go.drugbank.com/drugs/DB17476
    Investigational

    KF-0210 is a small molecule developed by Keythera Pharmaceuticals. It is being investigated for cancers.

  6. Drug

    TDI-01

    go.drugbank.com/drugs/DB19450
    Investigational

    TDI-01 is a small molecule is being developed by Beijing Tide Pharmaceutical.

  7. Drug

    Plasmin (Human)

    go.drugbank.com/drugs/DB22676
    Investigational

    The enzyme plasmin causes clot lysis by cleaving fibrin, a clot component.[L53453]

  8. Drug

    Trastuzumab emtansine

    go.drugbank.com/drugs/DB05773
    ApprovedInvestigational

    Trastuzumab emtansine, formerly called Trastuzumab-DM1 (T-DM1) is a first-in-class HER2 antibody drug conjugate (ADC) comprised of Genentech's trastuzumab antibody linked to ImmunoGen's cell-killing agent, DM1. T-DM1 combines two strateg...

  9. Drug

    Stavudine

    go.drugbank.com/drugs/DB00649
    ApprovedInvestigational

    A dideoxynucleoside analog that inhibits reverse transcriptase and has in vitro activity against HIV.

  10. Drug

    CHO Cells Recombinant Vaccine

    go.drugbank.com/drugs/DB15893
    Experimental

    The vaccine candidate is sponsored by Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. and is undergoing phase I clinical trials to evaluate safety and tolerability. … This vaccine candidate, developed in China, uses SARS-CoV-2 protein subunits that are entirely engineered, created, and secreted by Chinese Hamster Ovary (CHO) cells[A219758].